VYNE Therapeutics Inc. - stock earnings

VYNE Quarterly earnings

DateEarningsRevenue
2023Q4 -6.2 million USD 76000 USD
2023Q3 -6.6 million USD 114000 USD
2023Q2 -10.1 million USD 135000 USD
2023Q1 -5.6 million USD 99000 USD
2022Q4 -7.8 million USD 6000 USD
2022Q3 -9.5 million USD 167000 USD
2022Q2 -8.5 million USD 126000 USD
2022Q1 4.7 million USD 178000 USD
2021Q4 -11.6 million USD 2.3 million USD
2021Q3 -21.3 million USD 4.1 million USD
2021Q2 -19.9 million USD 4.3 million USD
2021Q1 -20.6 million USD 4.1 million USD
2020Q4 -23.2 million USD 4.3 million USD
2020Q3 -24.7 million USD 3.3 million USD
2020Q2 -167.4 million USD 11.7 million USD
2020Q1 -40.2 million USD 1.8 million USD
2019Q4 -21.5 million USD ? USD
2019Q3 -16.9 million USD ? USD
2019Q2 -16.5 million USD ? USD
2019Q1 -18.9 million USD ? USD
2018Q4 -17.6 million USD -10.6 million USD
2018Q3 -12.8 million USD ? USD
2018Q2 -8.3 million USD 10.1 million USD
2018Q1 -12.7 million USD 497000 USD
2017Q4 -9.3 million USD 2.8 million USD
2017Q3 -8.2 million USD 909000 USD
2017Q2 -6.2 million USD 449000 USD
2017Q1 -5.5 million USD 449000 USD
2016Q4 -4.8 million USD 450000 USD

VYNE Yearly earnings

DateEarningsRevenue
2023 -28.5 million USD 424000 USD
2022 -33.9 million USD 477000 USD
2021 -73.3 million USD 14.8 million USD
2020 -255.6 million USD 21.0 million USD
2019 -70.5 million USD 1.8 million USD
2018 -51.4 million USD 10.6 million USD
2017 -29.1 million USD 4.6 million USD
2016 -14.1 million USD 674000 USD
2015 -4.6 million USD ? USD

VYNE

Price: $2.53

52 week price:
1.67
8.73

Earnings Per Share: -2.72 USD

P/E Ratio: -0.23

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 68900

Market Capitalization: 39.1 million

Links: